[HTML][HTML] Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes
Journal of Thoracic Oncology, 2019•Elsevier
Introduction EGFR-mutant lung cancers are clinically and genomically heterogeneous with
concurrent RB transcriptional corepressor 1 (RB1)/tumor protein p53 (TP53) alterations
identifying a subset at increased risk for small cell transformation. The genomic alterations
that induce lineage plasticity are unknown. Methods Patients with EGFR/RB1/TP53-mutant
lung cancers, identified by next-generation sequencing from 2014 to 2018, were compared
to patients with untreated, metastatic EGFR-mutant lung cancers without both RB1 and TP53 …
concurrent RB transcriptional corepressor 1 (RB1)/tumor protein p53 (TP53) alterations
identifying a subset at increased risk for small cell transformation. The genomic alterations
that induce lineage plasticity are unknown. Methods Patients with EGFR/RB1/TP53-mutant
lung cancers, identified by next-generation sequencing from 2014 to 2018, were compared
to patients with untreated, metastatic EGFR-mutant lung cancers without both RB1 and TP53 …
Introduction
EGFR-mutant lung cancers are clinically and genomically heterogeneous with concurrent RB transcriptional corepressor 1 (RB1)/tumor protein p53 (TP53) alterations identifying a subset at increased risk for small cell transformation. The genomic alterations that induce lineage plasticity are unknown.
Methods
Patients with EGFR/RB1/TP53-mutant lung cancers, identified by next-generation sequencing from 2014 to 2018, were compared to patients with untreated, metastatic EGFR-mutant lung cancers without both RB1 and TP53 alterations. Time to EGFR–tyrosine kinase inhibitor discontinuation, overall survival, SCLC transformation rate, and genomic alterations were evaluated.
Results
Patients with EGFR/RB1/TP53-mutant lung cancers represented 5% (43 of 863) of EGFR-mutant lung cancers but were uniquely at risk for transformation (7 of 39, 18%), with no transformations in EGFR-mutant lung cancers without baseline TP53 and RB1 alterations. Irrespective of transformation, patients with EGFR/TP53/RB1-mutant lung cancers had a shorter time to discontinuation than EGFR/TP53- and EGFR-mutant –only cancers (9.5 versus 12.3 versus 36.6 months, respectively, p = 2 × 10-9). The triple-mutant population had a higher incidence of whole-genome doubling compared to NSCLC and SCLC at large (80% versus 34%, p < 5 × 10-9 versus 51%, p < 0.002, respectively) and further enrichment in triple-mutant cancers with eventual small cell histology (seven of seven pre-transformed plus four of four baseline SCLC versus 23 of 32 never transformed, respectively, p = 0.05). Activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like mutation signature was also enriched in triple-mutant lung cancers that transformed (false discovery rate = 0.03).
Conclusions
EGFR/TP53/RB1-mutant lung cancers are at unique risk of histologic transformation, with 25% presenting with de novo SCLC or eventual small cell transformation. Triple-mutant lung cancers are enriched in whole-genome doubling and Activation-induced cytidine deaminase/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like hypermutation which may represent early genomic determinants of lineage plasticity.
Elsevier